Effective Treatments for High-Risk Endometrial Cancer
Author Information
Author(s): Tani Yoshinori, Nakamura Keiichiro, Yorimitsu Masae, Seki Noriko, Nakanishi Mie, Itou Hironori, Shimizu Miyuki, Yamamoto Dan, Takahara Etsuko, Masuyama Hisashi
Primary Institution: Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Hypothesis
Lymphadenectomy and chemotherapy improve outcomes for patients with FIGO stage IIC high-risk endometrial cancer.
Conclusion
Lymphadenectomy and chemotherapy resulted in better prognoses regarding both recurrence and survival in patients with FIGO 2023 stage IIC high-risk endometrial cancer.
Supporting Evidence
- The study included 473 patients treated between 2004 and 2023.
- Patients with FIGO stage IIC-H had significantly worse progression-free survival compared to those with IIC-I.
- Lymphadenectomy and chemotherapy significantly reduced recurrence rates.
Takeaway
Doctors found that certain surgeries and medicines help people with a serious type of cancer feel better and live longer.
Methodology
This study retrospectively analyzed patients with FIGO stage IC and IIC endometrial cancer who underwent various treatments and evaluated their survival outcomes.
Limitations
The study was retrospective and included a small sample size.
Participant Demographics
Median age was 66 years, with a range from 25 to 92 years.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website